M&A watch: Amgen and Onyx haggle over Kyprolis data in stalled buyout talks

Ryan McBride As sources tell Bloomberg, the companies have been stalled in their talks over Amgen's proposed $ 130-per-share acquisition of Onyx because Amgen wants data from an ...

Which are pharma’s top 4 innovators? Hint: It’s not the big guys

Tracy Staton There's been a lot of talk about a dearth of innovation in the pharma business. But some drugmakers don't lack creativity. In fact, a few of them actually made ...

E-detailing:Nearly Half of Doctors have Attended at Least One Presentation

mia.burns By Mia Burns Almost half of the physicians surveyed in the Kantar Media Sources & Interactions Study, March 2013 – Medical/Surgical Edition say that have participated ...

Forest, Almirall combo COPD drug stumbles as Big Pharma rivals race ahead

John Carroll Regulators at the FDA evidently found some problems with a new combo LAMA/LABA COPD therapy in late-stage development by Forest Laboratories and Almirall. FierceBiotech ...

South Africa’s Adcock still in exclusive buyout talks with CFR

Carly Helfand Adcock has received other offers, but its board has deemed them "less compelling" than CFR's. That's good news for CFR, as South Africa's Public ...

Alnylam Hemophilia Drug Garners Orphan Drug Status

barbara.lempert CAMBRIDGE, Mass., Aug 14, 2013 (AP) — The Food and Drug Administration has granted an “orphan drug designation” to a potential hemophilia treatment ...

Biotech dealmaking pace slows, but PhII remains popular

John Carroll Looking over the 416 licensing deals EvaluatePharma tracked for the first six months of the year, total upfronts and deal values for Phase II programs were well ahead of ...

Pharmalot… Pharmalittle… Good Morning

esilverman Good morning, everyone, and how are you today? Once again, delightful rays of sunshine and a lovely breeze are brightening the Pharmalot corporate campus. While ...

In-depth study examines impact of e-prescribing

mia.burns By Mia Burns As e-prescribing adoption continues to increase among physicians, the practice presents challenges and opportunities for pharma companies. Management and technology ...

Pfizer, Sanford-Burnham in Diabetes Deal

barbara.lempert Sanford-Burnham Collaborates with Pfizer to Identify Targets for Treatment of Insulin Resistance and Diabetes LAKE NONA, FLA., August 13, 2013 – Sanford-Burnham ...

Pharmalot… Pharmalittle… Good Morning

esilverman Rise and shine, everyone, another busy day is on the way. After all, this is the middle of the week. A long to-do list aside, we are pleased to report that a strong ...

GW Opens IND for Phase III Sativex Trial

barbara.lempert GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for ...
Page 10 of 38« First...89101112...2030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS